Back to All

Transfer of Shares and Director_PDMR Shareholding

7 April, 2021

Diaceutics PLC

(“Diaceutics” or the “Company”)

Transfer of Shares and Director/PDMR Shareholding

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, has today been informed that Philip White has made the following transfers of a total of 1,119,941 ordinary shares of £0.002 each in the Company (“Ordinary Shares”) to his former spouse as detailed below.

On 6th April 2021, Philip White transferred 615,041 Ordinary Shares in the Company held in his own name and 504,900 Ordinary Shares in the Company held in his SIPP (the Philip White Tyres Pension Trust 81810) to Jemma White and The Xafinity SIPP re Jemma White, respectively, both for nil consideration.

As a result of this transfer, the beneficial holding of Philip White and his connected parties in the Company is 1,906,389 Ordinary Shares, representing 2.27% of the Company's issued share capital.

Enquiries:

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer


 


Cenkos Securities plc (Nominated adviser and broker)

+44 (0)207 397 8900

Callum Davidson / Giles Balleny


Michael Johnson (Sales)


 


Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893





About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX – our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world’s leading pharmaceutical companies. DXRX – the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world’s largest repository of diagnostic testing data on one secure platform. www.diaceutics.com

About DXRX – The Diagnostic Network®

DXRX is Diaceutics’ proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.